Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone deacetylase 1, 2, 3, and 10 are zinc-dependent enzymes that remove acetyl groups from lysine residues on histone tails, promoting chromatin condensation and transcriptional repression. HDACs also modify various non-histone proteins, affecting cellular processes such as cell cycle progression, apoptosis, and DNA repair. While HDAC1, HDAC2, and HDAC3 belong to class I HDACs and are mostly nuclear, HDAC10 belongs to class IIb and has unique polyamine deacetylase activity. Aberrant activity or expression of these enzymes is implicated in cancer and other diseases, making them important therapeutic targets for HDAC inhibitors[2][3][4][6][7].
Inhibitors bind the HDAC catalytic domain (often Zn2+-dependent), block deacetylation of histone and non-histone substrates, resulting in hyperacetylation and altered gene expression, commonly leading to cell cycle arrest, apoptosis, or differentiation in cancer cells[2][3][1]. HDAC10 is distinct in being a polyamine deacetylase, not a true histone deacetylase[4].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone deacetylase 1, Histone deacetylase 2, Histone deacetylase 3, Histone deacetylase 10 (HDAC1, HDAC2, HDAC3, HDAC10).